HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs.
The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement. The upcoming call will provide investors and stakeholders with insights into the company's commercial progress and pipeline developments.
The full press release is available at https://ibn.fm/yN939. For the latest news and updates relating to BEAT, visit the company's newsroom at https://ibn.fm/BEAT.
This announcement matters because it highlights HeartBeam's advancement in cardiac monitoring technology, which could significantly improve early detection and management of heart conditions, potentially reducing hospitalizations and saving lives. The limited commercial launch for arrhythmia assessment represents a key milestone in bringing this innovative technology to patients and healthcare providers.
